Archives
-
SFRP1, Wnt/β-Catenin, and Oral Fibrosis
2026-09-15
The reference study identifies SFRP1 as a potential regulator of oral submucous fibrosis by linking reduced SFRP1 expression with neutrophil infiltration, fibrosis, and increased Wnt/β-catenin pathway activity. Using arecoline-induced mouse and cellular models, the authors show that SFRP1 overexpression reduces fibrotic and inflammatory features, whereas pathway activation counteracts these effects.
-
CHK1 Inhibition in ER/PR-Stratified Breast Cancer
2026-09-14
The reference study shows that checkpoint kinase 1 (CHK1) is not a uniformly effective breast cancer target: its therapeutic value depends on estrogen-receptor, progesterone-receptor, and HER2 status. CHK1 inhibition enhanced adriamycin sensitivity in ER−/PR−/HER2− models but mainly produced single-agent activity in ER+/PR+/HER2− models, providing a framework for biomarker-guided treatment design.
-
CTP Solution and the Translational Path to p21 mRNA
2026-09-14
A mechanistic and translational analysis of how defined CTP input supports p21 mRNA workflows, using recent intravesical p21 mRNA–LNP research to connect nucleotide quality, RNA synthesis, localized delivery, and preclinical decision-making.
-
WZ4003 Workflows for NUAK1/2 Research
2026-09-13
WZ4003 is a selective NUAK1/2 inhibitor for connecting kinase engagement with measurable changes in MYPT1 phosphorylation, migration, proliferation, invasion, and pathological tau. This practical guide separates evidence-backed applications from starting conditions for cancer and brain-slice experiments.
-
Eudragit S 100-Coated LNPs for Oral RNA Delivery
2026-09-12
Haque, Shrestha, and Mattheolabakis developed a pH-responsive Eudragit S 100 coating for lipid nanoparticles containing RNA. The coating protected payloads under simulated gastric conditions while preserving transfection after exposure to simulated gastrointestinal fluids, supporting further investigation of non-injectable RNA delivery.
-
Machine Learning Predicts LNPs for mRNA Vaccines
2026-09-11
Wang and colleagues developed a LightGBM model from 325 mRNA vaccine lipid nanoparticle formulations and reported an R² above 0.87 for predicting IgG responses. The study combined computational prediction with mouse validation and molecular dynamics, showing how formulation screening may be accelerated while still requiring experimental confirmation.
-
LG 101506: RXR Modulator Workflow Guide
2026-09-11
LG 101506 enables controlled perturbation of RXR biology in cancer and metabolic models without conflating pathway modulation with direct PD-L1 targeting. This practical guide translates a TNBC immune-checkpoint study into dose design, orthogonal readouts, troubleshooting, and mechanism-focused assay workflows.
-
5-Aminolevulinic Acid HCl in Heme Research
2026-09-10
Explore how 5-Aminolevulinic acid HCl can function as a pathway probe rather than merely a heme precursor. This article translates new Salmonella–macrophage findings into practical assay-design guidance while distinguishing bacterial haem biology from mammalian photodynamic applications.
-
Reparixin for IL-8–CXCR1/2 Mechanism Studies
2026-09-10
Reparixin provides a receptor-level way to test whether IL-8–CXCR1/2 signaling connects bacterial extracellular vesicles with tumor-cell growth and neutrophil recruitment. This workflow combines EV comparison, pharmacological blockade, chemotaxis testing, and tissue-injury models while separating evidence-backed parameters from assay-development recommendations.
-
KPT-330 (Selinexor): CRM1 Inhibition in Cancer Research
2026-09-09
KPT-330 (Selinexor) is an orally bioavailable selective CRM1/XPO1 inhibitor that blocks nuclear export and supports preclinical apoptosis and cell-cycle studies. In basal-like triple-negative breast cancer models, KPT-330-containing combinations produced synergistic activity in vitro and improved tumor control in patient-derived xenografts.
-
Palonosetron: Pharmacology, PK, and CINV Evidence
2026-09-09
The 2010 reference study integrated receptor pharmacology, animal emesis models, pharmacokinetics, and randomized clinical evidence to define palonosetron as a highly selective 5-HT3 receptor antagonist with unusually sustained activity. Its most meaningful clinical finding was noninferiority to granisetron for acute symptoms and superiority for delayed chemotherapy-induced nausea and vomiting.
-
L-Phenylephrine: Designing Sex-Aware α1A Assays
2026-09-08
L-Phenylephrine is an adrenergic α1A receptor agonist that can refine cardiovascular assay design beyond simple vasoconstriction models. This guide translates sex-dependent angiotensin II hypertension findings into practical, mechanistically informed workflows for receptor, baroreflex, cardiomyocyte, and neural research.
-
ERCC1 Deficiency, p53, and Platinum Response
2026-09-08
Heyza and colleagues show that p53 status substantially modifies the response of ERCC1-deficient lung cancer cells to cisplatin and other interstrand crosslink stress. Their CRISPR-based models and patient-data analyses indicate that ERCC1 expression alone is an incomplete platinum-response biomarker because alternative repair and survival programs can preserve viability when p53 is defective.
-
2-Thio-dCTP and the Road to Mitotic Mechanism
2026-09-07
This thought-leadership article connects 2-Thio-dCTP chemistry with emerging insights into SCP4-mediated H3T3 dephosphorylation and chromosome stability. It provides a translational framework for validating modified-nucleotide incorporation, separating established findings from exploratory chromatin applications, and selecting fit-for-purpose DNA synthesis workflows.
-
Cx43/NF-κB Signaling in AngII Macrophage Polarization
2026-09-07
The reference study identifies a connexin 43–NF-κB pathway through which angiotensin II promotes pro-inflammatory M1 polarization in RAW264.7 macrophages. Its combined use of molecular, cytokine, phenotypic, and pharmacological readouts provides a useful framework for testing how Cx43-directed interventions influence inflammatory macrophage biology.